自身免疫性炎症性风湿病患者在改善病情抗风湿药治疗下接种COVID-19疫苗后体液免疫应答不同但细胞免疫应答相似
研究纳入92例接受TNFi、IL-17i、JAKi或甲氨蝶呤治疗的类风湿关节炎、中轴型脊柱关节炎或银屑病关节炎患者,评估两剂疫苗接种后体液与细胞免疫应答。首剂后仅37.8%患者出现中和抗体,第二剂后94.5%产生中和抗体,IL-17i组滴度最高,MTX联用组滴度较低但未达显著,各治疗间T细胞免疫相似。
要点
- 首剂疫苗后仅37.8%患者出现中和抗体,第二剂后升至94.5%。
- IL-17i组中和抗体滴度最高,MTX联用组滴度较低但未达统计学显著。
- 各治疗间活化T细胞频率与细胞因子谱相似。
核心结论
- 即使不同用药的AIRDs患者对SARS-CoV-2刺突蛋白中和抗体和IgG血清转化不足,第二剂接种几乎覆盖所有患者 regardless of DMARDs therapy,IL-17i者结局更好。
- bDMARD/tsDMARD或csDMARD治疗对细胞免疫应答未发现差异。
研究设计与样本
- 纳入接受TNFi、IL-17i(b-DMARDs)、JAKi(ts-DMARD)或甲氨蝶呤(MTX,csDMARD)单用或联用的类风湿关节炎、中轴型脊柱关节炎或银屑病关节炎患者。
- 几乎所有患者接种mRNA疫苗,4例采用异源方案。
- 在首剂和 second 疫苗接种后4周评估SARS-CoV-2刺突蛋白中和能力与IgG水平,并定量T细胞活化标志物及关键细胞因子产生。
主要发现
- 共纳入92例患者,中位年龄50岁,50%女性,33.7%接受TNFi,26.1%接受IL-17i,26.1%接受JAKi(均单用或与MTX联用),14.1%仅接受MTX。
- 首剂疫苗接种后仅37.8%患者出现中和抗体,第二剂后多数(94.5%)产生中和抗体。
- IL-17i组中和抗体滴度最高,与其他作用机制相比。
- MTX联用组滴度低于b/tsDMARD单药组,即使未达统计学显著。
- 中和抗体与SARS-CoV-2刺突蛋白IgG滴度相关性良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The effect of different modes of immunosuppressive therapy in autoimmune inflammatory rheumatic diseases (AIRDs) remains unclear. We investigated the impact of immunosuppressive therapies on humoral and cellular responses after two-dose vaccination. METHODS: Patients with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis treated with TNFi, IL-17i (biological disease-modifying antirheumatic drugs, b-DMARDs), Janus-kinase inhibitors (JAKi) (targeted synthetic, ts-DMARD) or methotrexate (MTX) (conventional synthetic DMARD, csDMARD) alone or in combination were included. Almost all patients received mRNA-based vaccine, four patients had a heterologous scheme. Neutralising capacity and levels of IgG against SARS-CoV-2 spike-protein were evaluated together with quantification of activation markers on T-cells and their production of key cytokines 4 weeks after first and second vaccination. RESULTS: 92 patients were included, median age 50 years, 50% female, 33.7% receiving TNFi, 26.1% IL-17i, 26.1% JAKi (all alone or in combination with MTX), 14.1% received MTX only. Although after first vaccination only 37.8% patients presented neutralising antibodies, the majority (94.5%) developed these after the second vaccination. Patients on IL17i developed the highest titres compared with the other modes of action. Co-administration of MTX led to lower, even if not significant, titres compared with b/tsDMARD monotherapy. Neutralising antibodies correlated well with IgG titres against SARS-CoV-2 spike-protein. T-cell immunity revealed similar frequencies of activated T-cells and cytokine profiles across therapies. CONCLUSIONS: Even after insufficient seroconversion for neutralising antibodies and IgG against SARS-CoV-2 spike-protein in patients with AIRDs on different medications, a second vaccination covered almost all patients regardless of DMARDs therapy, with better outcomes in those on IL-17i. However, no difference of bDMARD/tsDMARD or csDMARD therapy was found on the cellular immune response.
引用
- Andreica I, Blazquez-Navarro A, Sokolar J, et al. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination. RMD Open. 2022. PMID: 36104115. doi:10.1136/rmdopen-2022-002293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。